A Generic Drug Face-Off Sends Mylan Soaring 19%


The surprising FDA approval of Mylan's generic version of Teva Pharmaceutical's top-selling multiple sclerosis drug Copaxone is sending shares higher today. After the Food and Drug Administration surprisingly gave a green light to the company's Copaxone knockoff, shares in Mylan Inc. As a refresher, Copaxone is the most prescribed multiple sclerosis drug and it represents about 20% of Teva Pharmaceutical's sales.



from Biotech News